By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Biopôle III
Route de la Corniche 9B
  Epalinges  CH-1066  Switzerland
Phone: 41-21-651-92-20 Fax: 41-21-651-92-21



Company News
Anergis Completes Patient Recruitment In Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT 2/8/2017 7:39:43 AM
Anergis Release: Biopharma Appoints Klaus Schollmeier As New Chairman Of The Board Of Directors 1/24/2017 10:37:10 AM
Anergis To Present New Data On Lead Compound AllerT At The 35th European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2016 6/7/2016 1:03:05 PM
Anergis Closes CHF 5 Million Financing Round Extension To Conduct Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT 4/4/2016 9:23:30 AM
Anergis To Present Three Scientific Posters At 34th European Academy of Allergology and Clinical Immunology Congress 2015 6/4/2015 8:56:55 AM
Anergis Appoints Kim Simonsen As Chief Development Officer 6/2/2015 9:39:32 AM
Anergis Announces Completion Of Treatment In AllerT Phase II Dose-Ranging Trial 4/1/2015 9:27:07 AM
Anergis Presents Sustained Efficacy Data From Its Allert Phase 2b Trial At The AAAAI Annual Meeting 2/23/2015 10:50:02 AM
Anergis Granted U.S. Patent For Ragweed Allergy Vaccine AllerR 12/19/2014 10:41:18 AM
Anergis Starts Phase II Dose Ranging Trial With Birch Pollen Allergy Vaccine AllerT 12/11/2014 6:40:00 AM